Towards Healthcare
Osteoarthritis Market Size Envisioned at USD 19.15 Billion in 2032

Osteoarthritis Market Size Envisioned at USD 19.15 Billion in 2032

Status: Published Category: Therapeutic Area Insight Code: 5136 Format: PDF / PPT / Excel

The osteoarthritis market size is projected to boost from USD 8.60 billion in 2023 to reach around USD 19.15 billion in 2032 with an 8.4% CAGR over the forecast period 2024 to 2032.

Osteoarthritis Market Size 2023 - 2032

Unlock Infinite Advantages: Subscribe to Annual Membership

Report Highlights:

  • Knee osteoarthritis being the most prevalent cause of wear and tear dominated the market with over 49% market share in 2023.
  • Imaging tests in diagnosis ruled the market in 2023.
  • North America exhibited huge market share of 38% in 2023.

According to the Centers for Disease Control and Prevention, osteoarthritis constituted 2.5% of the total health issues experienced by individuals in 2023, and it accounted for 20% of the overall burden attributed to musculoskeletal conditions.

Osteoarthritis affects around 3.3 to 3.6% of people around the world. It's a significant cause of disability for about 43 million individuals, ranking it as the 11th most disabling condition globally. In the United States, around 80% of people over 65 show signs of osteoarthritis on X-rays, but only 60% of them feel symptoms. This is because changes in the X-ray images don't always mean the joint pain someone feels is directly caused by osteoarthritis.

A common joint ailment known as osteoarthritis develops when the layer of cartilage that protects the bony ends of your bones wears down over time. In the hands, hips, and knees among other afflicted joints, this may result in pain, stiffness, and decreased flexibility.

Highlights of Osteoarthritis

  • Age: As people age, their chance of developing osteoarthritis rises.
  • Sex: After the age of fifty,  women are more likely than men to develop osteoarthritis.
  • Obesity: Excess weight increases joint stress, especially on weight-bearing joints like the knees knees, and hips. The likelihood of osteoarthritis in that joint is raised by this stress. Furthermore, obesity may have metabolic consequences that raise the chance of osteoarthritis.
  • Genetics: An increased risk of developing osteoarthritis is seen in those with osteoarthritis in their families.
  • During 2020–21, approximately $4.3 billion was used for the care and handling of osteoarthritis, which accounted for 2.9% of the entire healthcare system spending and 29% of the spending directed towards all musculoskeletal conditions.

Proper treatment of osteoarthritis is crucial because it helps manage symptoms, improve joint function, and enhance overall quality of life. While it may not be curable, appropriate care can slow down the progression of the disease and alleviate discomfort. Treatment options include lifestyles modification like exercise and weight management, medications to manage pain and inflammation, and in some cases, surgical interventions. Early diagnosis and intervention are key to preventing further joint damage and maintaining an active lifestyles.

Number of People (in Thousands) with Hip and Knee Osteoarthritis in the UK

Ignoring osteoarthritis can result in increased pain, reduced mobility, and potential disability. By managing the condition appropriately, individuals can lead more comfortable lives, staying active and enjoying daily activities without the limitations imposed by joint pain and stiffness. Regular medical check-ups adherence to prescribed treatments, and a healthy lifestyle are essential for managing osteoarthritis effectively.

Aging and Obesity are Causing More Cases of Osteoarthritis

As people get older, their joints can wear down, leading to a common condition called osteoarthritis. This is more likely to happen as we age. The increasing number of people dealing with obesity is significant factor. Carrying extra weight puts extra stress on joints, making them more prone to osteoarthritis.

For instance,

  • According to the World Health Organization, because osteoarthritis is more common among older adults (with about 70% aged 55 and older), it's expected to become even more common as the population ages. It usually starts in the late 40s to mid-50s, but it can also affect younger people, like athletes or those who injure their joints. Around 60% of people with osteoarthritis are women.

Imagine joints as cushions over time, they can become worn out. So, an aging population and rising obesity rates contribute to the growth of osteoarthritis cases. This condition mainly affects the knees, hips, and hands, causing pain and stiffness. As our population gets older and more people gets to struggle with excess weight, the demand for solutions to manage and treat osteoarthritis rises. Medical advancement and increased awareness are crucial in addressing this growing health concern. Research and innovation therapies aim to provide better options for those affected by osteoarthritis, enhancing the quality of life for many individuals.

New Technology Offers Hope For Fixing Damaged Joints

Technological advancement plays a crucial role in shaping the market of osteoarthritis. These innovations primarily focus on developing more effective and patient-friendly therapies. One notable trend involves the rise of regenerative medicines, where stem cell therapy and tissue engineering offer promising avenues for repairing damaged joint tissues. These approaches aim to address the root cause of osteoarthritis, providing long-lasting relief.

For instance,

  • Mesenchymal stem cells (MSCs) are the most effective type of stem cell for tissue engineering and implantation in treating osteoarthritis.

Minimally invasive procedures have gained popularity due to their reduced impact on patients. Arthroscopy, a common minimally invasive technique, involves small incisions and specialized tools to visualize and treat joint problems. Patients experience quicker recovery times and less postoperative discomfort compared to traditional open surgeries. The demand for such procedures is fueled by the growing preference for outpatient treatments and shorter hospital stays.

In Drug development, biologics have emerged as a breakthrough. These medications, derived from living organisms, target specific molecules involved in the inflammatory process associated with osteoarthritis. This precision enhances treatment effectiveness while minimizing side effects. Advanced imaging techniques, such as MRI and CT scans, aid in early and accurate diagnosis, allowing healthcare professionals to intervene at the onset of symptoms. This proactive approach aligns 3D printing has revolutionized the production of customized implants. This technology enables the creation of patient-specific joint replacement, improving the overall fit and functionality. Customized implants contribute to better outcomes, especially in complex cases.

For instance,

  • In March 2023, Stryker unveiled a new product known as Mako Total Knee 2.0. This innovative tool utilizes advanced Mako SmartRobotics technology, comprising 3D CT-based planning, customized haptic technology, and intelligent data analytics. These components have demonstrated superior outcomes compared to traditional manual surgery for individuals undergoing total knee, hip, and partial knee procedures. Stryker introduced this product to enhance their product lineup and strengthen their business further.

Telemedicine now allows patients to easily connect with healthcare professionals to monitor and manage osteoarthritis. This virtual method boosts patient involvement, enables timely treatment, and eases pressure on healthcare systems.

The Role of Hyaluronic Acid Injections

Hyaluronic acid is a substance found naturally in our bodies, particularly in our joints and eyes. It acts like a lubricant and shock absorber, helping joints move smoothly and comfortably.  In osteoarthritis, the cartilage that cushions our joints wears away, leading to pain, stiffness, and swelling. Hyaluronic acid injections are being used as a treatment for osteoarthritis to help ease these symptoms. When injected into the joint, hyaluronic acid acts as a lubricant, reducing friction and pain during movement. It also helps to improve the quality of the joint fluid, providing better cushioning and support.

Studies have shown that hyaluronic acid injections can help reduce pain and improve joint function in people with osteoarthritis, particularly in the knee.

  • Insurance may cover the cost of hyaluronic acid injections for osteoarthritis, but you may need pre-authorization. It's important to confirm with your insurance provider before beginning treatment, as each injection can range from $350 to $500. Typically, insurance only covers one series of injections every six months.

The treatment is usually administered as a series of injections given over several weeks, and the effects can last for several months. Hyaluronic acid injections are generally considered safe, with minimal side effects such as temporary pain or swelling at the injection site.

Not everyone with osteoarthritis may benefit from hyaluronic acid injections, and it may not be suitable for those with certain medical conditions or allergies. It's essential to discuss with your healthcare provider if hyaluronic acid injections are right for you and to understand the potential benefits and risks.

For instance,

  • Hyaluronic acid injections may not be effective for everyone. They are most beneficial for people with mild to moderate osteoarthritis, but their effectiveness for those with severe arthritis is uncertain, warned Scott Rodeo, MD, co-director of the Tissue Engineering, Regeneration, and Repair Program at Weill Medical College of Cornell University in New York.

Hyaluronic acid offers a promising treatment option for osteoarthritis, providing relief from pain and improving joint function, thus helping people with osteoarthritis live more comfortably and actively.

Need for Personalized Therapies

Creating personalized therapy for osteoarthritis faces challenges because each patient's condition is unique. Traditional treatments often use a "one-size-fits-all" approach, but osteoarthritis can vary greatly from person to person. To make personalized treatments, scientists must thoroughly study and understand factors like genetic differences and the specific characteristics of each person's affected joints. Developing personalized therapies requires a lot of research and development. Scientists have to look closely at each patient's details, such as genetic markers and the specific conditions of their affected joints.

This in-depth understanding is needed for customizing treatments that address the specific nuances of osteoarthritis in an individual. The complexity of customization poses a significant challenge. Unlike mass-produced medications, personalized therapies require a more intricate approach. This complexity not only extends the time required for research but also increases the overall cost of developing these customized treatments.

Additionally, regulatory approval for personalized therapies adds another layer of complexity. Health authorities need robust evidence of safety and efficacy, which can be challenging to establish when dealing with individualized treatment. The aging population compounds these challenges osteoarthritis is more prevalent in older individuals, and as the global population ages, the demand for effective, personalized treatment is on the rise. This creates a sense of urgency for researchers and pharmaceutical companies to overcome the hurdles and develop innovative solutions.

Geographical Landscape

The osteoarthritis market in North America includes factors like prevalence rates, treatment options, and healthcare infrastructure. In the United States, osteoarthritis is a big concern, especially among older people.

Age Adjusted Percentage of Adults with Arthritis, United States, 2022

For instance,

  • By 2030, it's projected that 67 million Americans will have arthritis. Globally, around 10% of men and 18% of women aged over 60 experience knee osteoarthritis.

There are many treatments available, from medications to surgery, and a lot of research is being done to find new therapies. Canada has similar trends, with more people getting osteoarthritis and efforts to improve access to care. There's a focus on finding better treatments and making sure people can get the care they need.

Osteoarthritis poses a significant health challenge in the Asia Pacific region due to reasons such as aging populations, increasing obesity rates, and improved awareness. Healthcare systems and treatment availability differ among countries, with some having better access to advanced therapies while others face barriers like cost and availability. Cultural and dietary practices also play a role in influencing osteoarthritis prevalence and management across the region.

Competitive Landscape

The osteoarthritis market involves companies making medicines, devices, and therapies for treating osteoarthritis. They compete by offering different products, prices, and marketing strategies. Factors like product effectiveness, safety, regulatory approvals, and brand reputation affect competition. Pharmaceutical companies make drugs like pain relievers and anti-inflammatories. Medical device makers create implants and braces for joint treatment. Biotech firms focus on innovative therapies like drugs that slow down osteoarthritis or help tissue regrowth. Healthcare providers also play a role by offering treatments like physical therapy and joint injections. The market is always changing due to research, new technology, and companies teaming up or buying each other. They aim to meet the needs of osteoarthritis patients and stay ahead of competitors.

Recent Developments

  • In September 2021, Novartis announced that LNA043 received fast-track designation from the US Food and Drug Administration (FDA) for knee osteoarthritis treatment.
  • In February 2021, Moebius Medical revealed that MM-II, an innovative treatment option for knee osteoarthritis symptoms, is undergoing Phase IIb clinical trials. These trials aim to compare the effectiveness and safety of different MM-II doses with placebo in patients experiencing knee osteoarthritis symptoms.

Osteoarthritis Market Players

  • Zimmer Biomet
  • Pfizer
  • GlaxoSmithKline
  • Bayer Consumer Health
  • Merck & Co.
  • Mylan N.V.
  • Anika Therapeutics Inc.
  • Huons
  • Johnson & Johnson

Osteoarthritis Market Segments

By Type

  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Others

By Diagnosis

  • Imaging Tests
  • Blood Tests
  • Joint Fluid Analysis

By Treatment

  • Medication
    • Analgesic
    • NSAIDs
    • Counterirritants
    • Corticosteroids
    • Hyaluronic Acid
  • Supportive Devices
  • Surgery

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Namrata Bukshet is not just a market researcher; she is a detective, a storyteller, and a champion for healthier lives. Her journey began with a Bachelor of Pharmacy degree and a thirst for knowledge that led her to pursue a Post Graduate Diploma in Pharmaceutical Management. Her curiosity for consumer behaviour and market trends burned bright. She delved deep into the world of lifestyle disorders, conducting extensive research that sheds light on the intricate dance between personal choices and societal pressures. This exploration culminated in a groundbreaking paper on E-Biz: Indias 1st G2B Online Portal, presented at an international conference, where her insights resonated with a global audience. But Namrata has impact extends far beyond a single paper. Her expertise has shaped the very landscape of market research and pharmaceuticals. Her keen eye for detail and unwavering commitment to understanding the why behind consumer behaviour have made her a sought-after professional in the industry. She is the decoder ring that unlocks the secrets hidden within data, the translator who turns complex trends into actionable insights. As she continues to unravel the mysteries of consumer behaviour, she paves the way for a future where healthcare is not just about treatment but about understanding the why and building a bridge to a healthier world, one insightful discovery at a time.


Osteoarthritis is a degenerative joint disease that causes pain, stiffness, and swelling in the affected joints. It occurs when the protective cartilage that cushions the ends of bones wears down over time.

North America lead the market of osteoarthritis.

Hyaluronic acid is commonly used in the treatment of osteoarthritis to provide lubrication and cushioning to the affected joints, reducing pain and inflammation. It can be administered through injections directly into the joint space, offering localized relief.

World Health Organization, Arthritis Foundation, Food and Drug Administration, National Institute of Health, Centers for Disease Control and Prevention.